Keywords: Ipsen, Photocure, Hexvix, Bladder cancer, Diagnostic

Ipsen enters deal with Photocure to commercialize Hexvix

Article | 28 September 2011

Print This

French drugmaker Ipsen (Euronext: IPN) has entered into a partnership with Norway-based Photocure (OSE: PHO) to commercialize the latter’ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in